ENSURING COMPETITIVENESS THROUGH CLINICAL TRIALS AND ENTERING JAPANESE MARKET

Starting a commercial treatment business in Japan: Clinics and CPC contracts (Approval of sales permit: April)
Participated in the fourth R&D-oriented high-quality pharmaceutical and biological growth company IR (IPIR/Invest Fair 2017-Season IV): co-hosted by the Korea New Drug Research Association and the Korea Health Industry Development Institute
Nov 2017, completion of liver cancer non-clinical trials (SK-Hep1 cell, International St. Mary’s Hospital)
Sep 2017, transfer of patent for formulation and manufacturing method of α-lipoic acid nanoparticles with improved stability (KR10-1021619)
Jul 2017, signed an MOU with Japanese company D for the immune cell therapy business
Jul 2017, signed a technology transfer confidentiality agreement with Japanese company F
Jul 2017, completion of non-clinical trials of brain tumors (U87MG cell, Biotoxtech)